A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

FDA COVID-19 Update for July 9, 2020

July 9, 2020

FDA today continued to take action in the ongoing response to the COVID-19 pandemic:

  • Today, a U.S. District Court in Florida granted a motion for default judgment and a permanent injunction against the Genesis II Church of Health and Healing, Jonathan Grenon, and Jordan Grenon for violating federal law by distributing their product, “Miracle Mineral Solution,” an industrial bleach that the defendants claim is a cure for COVID-19 and other serious diseases. The order issued today permanently prohibits the defendants from selling or distributing unapproved or misbranded products, such as Mineral Miracle Solution (MMS). In prior warning statements, the FDA has urged consumers not to purchase or use MMS, explaining that drinking MMS is the same as drinking bleach and can cause dangerous side effects, including severe vomiting, diarrhea, and life-threatening low-blood pressure. In May, the federal judge entered a preliminary injunction against the Genesis II Church of Health and Healing and four individual defendants associated with the entity.
  • Testing updates:
    • To date, the FDA has currently authorized 171 tests under EUAs; these include 142 molecular tests, 27 antibody tests, and 2 antigen tests.
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy